138 related articles for article (PubMed ID: 15344541)
1. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Yoshino T; Shio S; Hayakumo T; Kawai K
Nihon Rinsho; 2004 Aug; 62(8):1504-9. PubMed ID: 15344541
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
Habu Y; Fukui Y; Maruno T; Hisatsune H; Kawai K
Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
5. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Gregor JC
Am J Manag Care; 2000 Aug; 6(8):934-5. PubMed ID: 11186505
[No Abstract] [Full Text] [Related]
8. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
9. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
[TBL] [Abstract][Full Text] [Related]
10. Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Mine S; Fujisaki T; Tabata T; Matsuoka H; Iida T; Yamada S; Tanaka Y; Morimoto I; Eto S; Aibe T
Am J Gastroenterol; 2000 Feb; 95(2):381-6. PubMed ID: 10685739
[TBL] [Abstract][Full Text] [Related]
11. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Ofman JJ; Yamashita BD; Siddique RM; Larson LR; Willian MK
Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
14. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of gastroesophageal reflux disease and its complications.
Richter JE
Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
[TBL] [Abstract][Full Text] [Related]
16. PPIs vs H2RAs for erosive reflux esophagitis.
King VJ
J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
[No Abstract] [Full Text] [Related]
17. Effectiveness of proton pump inhibitors: beyond cost.
Katz PO
Rev Gastroenterol Disord; 2004; 4 Suppl 4():S8-S15. PubMed ID: 15580146
[TBL] [Abstract][Full Text] [Related]
18. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Endo M; Sugihara K
Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
[TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastroesophageal reflux disease: to step or not to step.
McGuigan JE
Am J Gastroenterol; 2001 Jun; 96(6):1679-81. PubMed ID: 11419813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
